11/2017 |
Debt |
|
$3.5M |
New Enterprise Associates
AstraZeneca
Johnson & Johnson Innovation
Hatteras Venture Partners
Fletcher Spaght Ventures
Syno Capital
|
3/2015 |
Series C |
|
$0 |
AstraZeneca
Fletcher Spaght, Inc.
Johnson &a; Johnson Development Corporation
New Enterprise Associates
Hatteras Venture Partners
AstraZeneca
Fletcher Spaght, Inc.
Johnson &a; Johnson Development Corporation
New Enterprise Associates
Hatteras Venture Partners
|
10/2007 |
Venture Round |
3 |
$6.6M |
Johnson &a; Johnson Development Corporation
Hatteras Venture Partners
Fletcher Spaght, Inc.
|
9/2018 |
Series D |
|
$0 |
AstraZeneca
Cormorant Asset Management
Johnson &a; Johnson Innovation – JJDC
Rock Springs Capital
Syno Capital
Fletcher Spaght, Inc.
Mountain Group Capital
Hatteras Venture Partners
New Enterprise Associates
Hatteras Venture Partners
AstraZeneca
Cormorant Asset Management
Johnson &a; Johnson Innovation – JJDC
Rock Springs Capital
Syno Capital
Fletcher Spaght, Inc.
Mountain Group Capital
Hatteras Venture Partners
New Enterprise Associates
Hatteras Venture Partners
|
1/2020 |
Post-IPO Equity |
|
$0 |
SFJ Pharmaceuticals
SFJ Pharmaceuticals
SFJ Pharmaceuticals
SFJ Pharmaceuticals
|
1/2017 |
Convertible Note |
|
$6.6M |
New Enterprise Associates
AstraZeneca
Johnson & Johnson Innovation
Hatteras Venture Partners
Fletcher Spaght Ventures
Syno Capital
|
10/2018 |
IPO |
|
$46M |
|
2/2018 |
Grant |
1 |
$2.8M |
National Institutes of Health
National Institutes of Health
|
11/2009 |
Debt Financing |
|
$1M |
|
11/2017 |
Debt Financing |
1 |
$7.5M |
Silicon Valley Bank
Silicon Valley Bank
|
6/2012 |
Series B |
5 |
$23M |
New Enterprise Associates
Johnson &a; Johnson Development Corporation
Hatteras Venture Partners
Fletcher Spaght, Inc.
Astellas Venture Management
New Enterprise Associates
|
1/2010 |
Series B |
5 |
$25M |
New Enterprise Associates
OSI Pharmaceuticals
Johnson &a; Johnson Development Corporation
Hatteras Venture Partners
Fletcher Spaght, Inc.
New Enterprise Associates
OSI Pharmaceuticals
|
3/2021 |
Post-IPO Equity |
|
$64.4M |
|
2/2002 |
Series A |
|
- |
Catalysta Ventures
Catalysta Ventures
|
11/2017 |
Convertible Note |
|
$1.5M |
New Enterprise Associates
AstraZeneca
Johnson & Johnson Innovation
Hatteras Venture Partners
Fletcher Spaght Ventures
Syno Capital
|
9/2018 |
Series D |
9 |
$34M |
Rock Springs Capital
Mountain Group Partners
New Enterprise Associates
Hatteras Venture Partners
AstraZeneca
Johnson & Johnson Innovation
Syno Capital
Fletcher Spaght Ventures, LP
Cormorant Asset Management
Johnson &a; Johnson Innovation – JJDC
Rock Springs Capital
Syno Capital
Fletcher Spaght, Inc.
Mountain Group Capital
AstraZeneca
Hatteras Venture Partners
New Enterprise Associates
Hatteras Venture Partners
|
1/2020 |
Post-IPO Equity |
1 |
$120M |
SFJ Pharmaceuticals
SFJ Pharmaceuticals
SFJ Pharmaceuticals
SFJ Pharmaceuticals
|
3/2015 |
Series C |
5 |
$40M |
AstraZeneca
AstraZeneca
|